What does it actually take to turn a scientific breakthrough into a drug patients can access?

In this episode, I look at the manufacturer side of the healthcare system, the part that absorbs scientific failure, funds long-shot bets, and then enters a second battle after the science succeeds. Because FDA approval is not the finish line. It is the point where a therapy enters the real commercial system: one shaped by patent clocks, launch pricing, payer resistance, formulary access, rebates, and budget pressure.

This is a story about the economics of failure, the logic of blockbuster drugs, and the central tension at the heart of modern pharma: scientifically essential, politically unpopular, financially powerful, and commercially constrained at the same time.

Between the lab bench and the patient sits a market that does not simply reward innovation. It prices it, filters it, delays it, and redistributes its value.

Timestamps

• 00:00 Intro: The Drug Exists. Access Still Breaks Down
• 05:44 FDA Approval Is Not the Finish Line
• 09:41 Inside the R&D Risk Machine
• 13:24 Why Most Drug Trials Fail
• 15:32 The Patent Clock Starts Early
• 24:39 Why U.S. Drug Prices Run Higher
• 29:19 The Gross-to-Net Bubble
• 40:16 The Pharma Paradox
• 44:05 The IRA Changes the Game
• 50:59 Invention Is Not Enough